Menu
Log in
Forgot password

   CHEMICAL CONSULTANTS NETWORK

Log in

Dr. Gregory J. Wells

Cecon LLC

 

Member profile details

First name
Dr. Gregory J.
Last name
Wells
Organization
Cecon LLC
 

Contact information

City
West Chester
State or Province
Pennsylvania
Zip Code
19382
Country
United States
Phone
(610) 585-7322
Phone (Alternate)
610-793-4599
 

Specialties and Services

Fields of Expertise
  • Analytical
  • Biochemistry
  • Environmental & Safety
  • Expert Witness
  • Medicinal Chemistry
  • Organic Chemistry
  • Pharmaceutical
  • Product Development
  • Project Management
  • Research and Development
  • Safety and Loss Prevention
  • Synthesis
  • Technical
  • Technology Transfer
Other Fields of Expertise
Organic Synthesis
Drug Discovery
Process R&D
Chemical Hygiene
Lab Safety
Chemical SOP and SDS preparation and revision
Summary
Dr. Gregory Wells, an organic and medicinal chemist, has over 25 years of laboratory, supervisory, and management experience at major pharmaceutical and biotech companies working in the fields of Drug Discovery and Chemical Process R&D.

Variously, as a Senior Scientist, Group Leader, Project Manager and Research Fellow, he has led teams of laboratory staff from technician/operator through senior level scientists working within cross-functional teams in a variety of therapeutic areas, including oncology, stroke, inflammation, and cardiovascular disease. He has also served as a Lab Safety and Chemical Hygiene Manager for a Medicinal Chemistry department of over 50 research staff, with responsibilities to ensure compliance with EPA and OSHA laboratory standards and has been certified as a HAZWOPER First Responder for laboratory accidents, chemical spills and injuries.

Dr. Wells is an author on 35 publications in major peer-reviewed journals and 15 related patents. He earned Ph.D. and M.S. degrees in organic chemistry from The Ohio State University under the mentorship of Dr. Leo A. Paquette.
Services
o Organic and Medicinal Chemistry Consulting

o Project Management for Drug Discovery and Process R&D
projects from early concept, planning, hit-to-lead, and
development up to pilot plant level

o Rational, structure-based design of novel, small molecule
drug candidates applied towards validated disease targets.

o Design and multi-step synthesis of complex organic compounds
from mg to multi-kg scales. Targets and therapeutic areas of
expertise have included:
- Kinase inhibitors, including ALK, c-Met, and JAK
(oncology)
- PARP-1 inhibitors (oncology)
- Cysteine protease inhibitors, particularly for Calpain
(stroke, hemorrhage)
- Angiotensin receptor antagonists and ACE inhibitors (CV)

o SAR lead optimization and proven solutions to PK/PD and ADMET
challenges.

o Standard or automated synthetic methodologies.

o Synthesis of clinical drug candidates under cGMP standards.

o Other services include:
- IP due diligence
- Technical and grant writing
- Technology transfer
- IND and NDA documentation
- Laboratory Safety and Chemical Hygiene Consulting,
including bench level expertise with EPA regulations,
OSHA lab standards and incident response.
More Services
Chemical inventory management solutions.
Chemical SOP and SDS document preparation and revision.
 

Additional Information

Patents
Pyrrolotriazines as ALK and JAK2 Inhibitors. Breslin, H. J.; Chatterjee, S.; Diebold, J. L.; Dorsey, B. D.; Dunn, D.; Gingrich, D. E.; Hostetler, G. A.; Hudkins, R. L.; Hunter, R.; Josef, K.; Lisko, J.; Mesaros, E. F.; Milkiewicz, K. L.; Ott, G. R.; Sundar, B. G.; Theroff, J. P.; Thieu, T.; Tripathy, R.; Underiner, T. L.; Weinberg, L.; Wells, G. J.; Zificsak, C. A.; US App. PCT/US09/69006 (2009).

Preparation of Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-Met Kinase Inhibitors. Ahmed, G.; Bohnstedt, A.; Breslin, H. J.; Burke, J.; Curry, M. A.; Diebold, J. L.; Dorsey, B.; Dugan, B. J.; Feng, D.; Gingrich, D. E.; Guo, T.; Ho, K.-K.; Learn, K. S.; Lisko, J. G.; Liu, R.-Q.; Mesaros, E. F.; Milkiewicz, K.; Ott, G. R.; Parrish, J.; Theroff, J. P.; Thieu, T. V.; Tripathy, R.; Underiner, T. L.; Wagner, J. C.; Weinberg, L.; Wells, G. J.; Tao, M.; Zificsak, C. A; US App. 20090221555 (2009).

2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors. Breslin, H. J.; Chatterjee, S.; Diebold, J. L.; Dorsey, B.; Dunn, D..; Gingrich, D. E.; Hostetler, G. A.; Hudkins, R. L.; Hunter, R.; Josef, K.; Lisko, J. G.; Mesaros, E. F.; Milkiewicz, K.; Ott, G. R.; Sundar, B. G.; Theroff, J. P.; Thieu, T.; Tripathy, R.; Underiner, T. L.; Weinberg, L.; Wells, G. J. International Patent WO 2010071885A1 (2008).

Preparation of Novel Multicyclic Compounds and Their Amino Acid Derivatives as Inhibitors of Enzymes such as Poly(ADP-ribose)polymerase. Chatterjee, S.; Diebold, J. L.; Dunn, D.; Hudkins, R. L.; Reddeppareddy, D.; Wells, G. J.; Zulli, A. L.; US App. 20060276497 (2006).

Peptide-containing -Ketoamide Cysteine and Serine Protease Inhibitors. Chatterjee, S.; Mallamo, J. P.; Bihovsky, R.; Wells, G. J.; US 7,001,907 (2006).

Peptide-containing -Ketoamide Cysteine and Serine Protease Inhibitors. Chatterjee, S.; Mallamo, J. P.; Bihovsky, R.; Wells, G. J.; US 6,703,368 (2004).

Benzothiazine Group-containing Cysteine and Serine Protease Inhibitors. Wells, G. J.; Bihovsky, R.; Tao, M.; US 5,952,328 (1999).

Cyclic Compounds Linked by a Heterocyclic Ring Useful as Inhibitors of Platelet Glycoprotein IIb/IIIa. Wells, G. J.; Wityak, J.; Parthasarathy, A.; DeGrado, W. F.; Jackson, S. A.; Mousa, S. A.; US 5,773,411 (1998).

Phosphorous-Containing Cysteine and Serine Protease Inhibitors. Mallamo, J. P.; Bihovsky, R.; Tao, M.; Wells, G. J.; US 5,639,732 (1997).

Substituted Pyrazole Angiotensin II Antagonists. Wells, G. J.; Carini, D. J.; Duncia, J. V.; US 5,315,013 (1994).

Substituted 1,2,3-Triazole Angiotensin II Antagonists. Wells, G. J.; Carini, D. J.; Duncia, J. V.; US 5,189,048 (1993).
More Patents
Substituted 1,2,3-Triazole Angiotensin II Antagonists. Wells, G. J.; Carini, D. J.; Duncia, J. V.; US 5,081,127 (1992).

Substituted 1,2,4-Triazole Angiotensin II Antagonists. Wells, G. J.; Carini, D. J.; Duncia, J. V.; US 5,093,346 (1992).

Substituted Pyrrole Angiotensin II Antagonists. Wells, G. J.; Carini, D. J.; Duncia, J. V.; US 5,043,349 (1991).

Treatment of Hypertension with 1,2,4-Triazole Angiotensin II Antagonists. Wells, G. J.; Carini, D. J.; Duncia, J. V.; US 5,015,651 (1991).
Publications
Selected Publications:

Allosteric Modulators of G Protein-Coupled Receptors. Wells, G. J. (Ed.); Kuduk, S. D.; Beshore, D. C.; Huang, X.; Dale, E.; Brodbeck, R. M.; Doller, D.; Szabo, G.; Keseru, G. M.; Hao, J.; Xiong, H.; Hurevich, M.; Talhami, A.; Shalev, D. E.; Gilon, C.; Curr. Topics Med. Chem., 14, 1735-1863 (2014).

Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-f][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors. Mesaros, E. F.; Thieu, T. V.; Wells, G. J.; Zificsak, C. A.; Wagner, J. C.; Breslin, H. J.; Tripathy, R.; Diebold, J. L.; McHugh, R. J.; Wohler, A. T.; Quail, M. R.; Wan, W.; Lu, L.; Huang, Z.; Albom, M. S.; Angeles, T. S.; Wells-Knecht, K. J.; Aimone, L. D.; Cheng, M; M. A.;Ator, Ott, G. R.; Dorsey, B. D.; J. Med. Chem., 55, 115 125 (2012).

2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation. Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Breslin, H. J.; Gingrich, D. E.; Huang, Z.; Lisko, J. G.; Mason, J. L.; Milkiewicz, K. L.; Thieu, T. V.; Underiner, T. L.; Wells, G. J.; Wells-Knecht, K. J.; Dorsey, B. D.; Bioorg. Med. Chem. Lett., 21, 7325-7330 (2011).

2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation. Wells-Knecht, K. J.; Ott, G. R.; Cheng, M.; Wells, G. J.; Breslin, H. J.; Gingrich, D. E.; Weinberg, L.; Mesaros, E. F.; Huang, A.; Yazdarian, M.; Ator, M. A.; Aimone, L. D.; Zeigler, K.; Dorsey, B. D.; Chem. Res. Tox., 24, 1994-2003 (2011).

2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity. Ott, G. R.; Wells, G. J.; Thieu, T. V.; Quall, M. R.; Lisko, J. G.; Mesaros, E. F.; Gingrich, D. E.; Ghose, A. K.; Wan, W.; Lu, L.; Cheng, M.; Albom, M. S.; Angeles, T. S.; Huang, Z.; Aimone, L. D.; Ator, M. A.; Ruggeri, B. A.; Dorsey, B. D.; J. Med. Chem., 54, 6328-6341 (2011).

Synthesis and Structure-Activity Relationships of Novel Pyrrolocarbazole Lactam Analogs as Potent and Cell-permeable Inhibitors of Poly(ADP-ribose)polymerase-1 (PARP-1). Wells, G. J.; Bihovsky, R.; Hudkins, R. L.; Ator, M. A.; Husten, J.; Bioorg. Med. Chem. Letters, 16, 1151-1155 (2006).

Synthesis and Structure-Activity Relationships of Novel Poly(ADP-ribose)polymerase-1 Inhibitors. Tao, M.; Park, C. H.; Bihovsky, R.; Wells, G. J.; Husten, J.; Ator, M. A.; Hudkins, R. L.; Bioorg. Med. Chem. Letters, 16, 938-942 (2006).

1,2-Benzothiazine 1,1-dioxide -Ketoamide analogues as potent Calpain I Inhibitors. Bihovsky, R.; Tao, M.; Mallamo, J. P.; Wells, G. J.; Bioorg. Med. Chem. Letters, 14, 1035-1038 (2004).
More Publications
Selected Publications (cont.):

1,2-Benzothiazine 1,1-dioxide P2-P3 Peptide Mimetic Aldehyde Calpain I Inhibitors. Wells, G. J.; Tao, M.; Josef, K. A.; Bihovsky, R.; J. Med. Chem., 44, 3488-3503 (2001).

P2-Achiral, P'-Extended -Ketoamide Inhibitors of Calpain I. Chatterjee, S.; Dunn, D.; Tao, M.; Wells, G. J.; Gu, Z.-Q.; Bihovsky, R.; Ator, M. A.; Siman, R.; Mallamo, J. P.; Bioorg. Med. Chem. Letters., 9, 2371-2374 (1999).

Calpain Inhibitors as Potential Treatment for Stroke and Other Neurodegenerative Diseases: Recent Trends and Developments. Wells, G. J.; Bihovsky, R.; Expert Opinion Therap. Patents, 8, 1707-1727 (1998).

Novel Peptidyl Phosphorous Derivatives as Inhibitors of Human Calpain I. Tao, M.; Bihovsky, R.; Wells, G. J.; Mallamo, J. P.; J. Med. Chem., 41, 3912-3916 (1998).

Potent Fluoromethyl Ketone Inhibitors of Recombinant Human Calpain I. Chatterjee, S.; Josef, K.; Wells, G. J.; Iqbal, M.; Bihovsky, R.; Mallamo, J. P.; Ator, M. A.; Bozyczko-Coyne, D.; Mallya, S.; Senadhi, S.; Siman, R.; Bioorg. Med. Chem. Letters, 6, 1237-1240 (1996).

Synthesis and Antiplatelet Activity of DMP757 Analogs. Wityak, J.; Fevig, J. M.; Jackson, S. A.; Johnson, A. L.; Mousa, S.; Parthasarathy, A.; Wells, G. J.; DeGrado, W. F.; Wexler, R. R.; Bioorg. Med. Chem. Letters, 5, 2097-2100 (1995).

Potent Fluoromethyl Ketone Inhibitors of Recombinant Human Calpain I. Chatterjee, S.; Josef, K.; Wells, G. J.; Iqbal, M.; Bihovsky, R.; Mallamo, J. P.; Ator, M. A.; Bozyczko-Coyne, D.; Mallya, S.; Senadhi, S.; Siman, R.; Bioorg. Med. Chem. Letters, 6, 1237-1240 (1996).

Synthesis and Antiplatelet Activity of DMP757 Analogs. Wityak, J.; Fevig, J. M.; Jackson, S. A.; Johnson, A. L.; Mousa, S.; Parthasarathy, A.; Wells, G. J.; DeGrado, W. F.; Wexler, R. R.; Bioorg. Med. Chem. Letters, 5, 2097-2100 (1995).

Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa. Jackson, S.; Harlow, R.; Dwivedi, A.; Parthasarathy, A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.; Wells, G. J.; Wexler, R. R.; Mousa, S.; DeGrado, W. F.; J. Amer. Chem. Soc., 116, 3220-3230 (1994).

Practical Synthesis and Regioselective Alkylation of Methyl 4(5)-(Pentafluoroethyl)-2-propylimidazole-5(4)-carboxylate to Give DuP532, a Potent Angiotensin II Antagonist. Pierce, M. E.; Carini, D. J.; Huhn, G. F.; Wells, G. J.; Arnett, J. F.; J. Org. Chem., 58, 4642-4645 (1993).
Miscellaneous
Selected Publications (cont.):

Rationale for the Chemical Development of Angiotensin II Receptor Antagonists. Wexler, R. R.; Carini, D. J.; Duncia, J. V.; Johnson, A. L.; Wells, G. J.; Chiu, A. T.; Wong, P. C.; Timmermans, P. B.; Amer. J. Hypertension, 5, 209S-220S (1992).

Angiotensin II Receptor Antagonists: From Discovery to Antihypertensive Drugs. Timmermans, P. B.; Carini, D. J.; Chiu, A. T.; Duncia, J. V.; Price, W. A.; Wells, G. J.; Wong, P. C.; Wexler, R. R.; Johnson, A. L.; Hypertension, 18, III136-III142 (1991).

Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)imidazoles as Potent, Orally Active Antihypertensives. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella III, J. B.; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S. -E.; Timmermans, P. B.; J. Med. Chem., 34, 2525-2547 (1991).

The Discovery of a New Class of Highly Specific Nonpeptide Angiotensin II Receptor Antagonists. Timmermans, P. B.; Carini, D. J.; Chiu, A. T.; Duncia, J. V.; Price, W. A.; Wells, G. J.; Wong, P. C.; Johnson, A. L.; Wexler, R. R.; Amer. J. Hypertension, 4, 275S-281S (1991).

Nonpeptide Angiotensin II Receptor Antagonists. Timmermans, P. B.; Carini, D. J.; Chiu, A. T.; Duncia, J. V.; Price, W. A.; Wells, G. J.; Wong, P. C.; Amer. J. Hypertension, 3, 599-604 (1990).

Nonpeptide Angiotensin II Receptor Antagonists: A Novel Class of Antihypertensive Agents. Timmermans, P. B.; Carini, D. J.; Chiu, A. T.; Duncia, J. V.; Price, W. A.; Wells, G. J.; Wong, P. C.; Wexler, R. R.; Johnson, A. L.; Blood Vessels, 27, 295-300 (1990).

Nonpeptide Angiotensin II Receptor Antagonists. Johnson, A. L.; Carini, D. J.; Chiu, A. T.; Duncia, J. V.; Price, W. A.; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Timmermans, P. B.; Drug News & Perspectives, 337-351 (1990).

The Discovery of Potent Nonpeptide Angiotensin II Antagonists: A New Class of Potent Antihypertensives. Duncia, J. V.; Chiu, A. T.; Carini, D. J.; Gregory, G. B.; Johnson, A. L.; Price, W. A.; Wells, G. J.; Wong, P. C.; Calabrese, J C.; Timmermans, P. B.; J. Med. Chem., 33, 1312-1329 (1990).
The ideas, advice and positions expressed by individual members of the Chemical Consultants Network are the member's own and not the responsibility of CCN or its sponsors, the American Chemical Society and the American Institute of Chemical Engineers.

© 2017 Chemical Consultants Network 

Chemical Consultants Nework is jointly supported by AlChE and ACS

Powered by Wild Apricot Membership Software